Instrument Inactif

Communiqués Altimmune Inc NYSE

Actions

US71714G1022

Recherche biotechnologique et médicale

Cours en clôture NYSE Autres places de cotation
- ^USD	-

03/08	Altimmune lance le recrutement des patients pour l'essai de phase 3 du pemvidutide dans la MASH	MT
28/07	Transcript : Altimmune, Inc. - Special Call

Communiqués

03/08	Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH	AQ
28/07	Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder	AQ
28/05	Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026	AQ
27/05	Altimmune to Participate in Upcoming Investor Conferences	AQ
27/05	New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026	AQ
13/05	Altimmune Announces First Quarter 2026 Financial Results and Business Update	AQ
13/05	Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026	AQ
06/05	Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
27/04	Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities	AQ
23/04	Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities	AQ
22/04	Altimmune Announces Proposed Underwritten Public Offering of Securities	AQ
06/03	Altimmune : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)	PU
05/03	Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates	AQ
02/03	Altimmune to Participate in Upcoming Investor Conferences	AQ
26/02	Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026	AQ
29/01	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock	AQ
28/01	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock	AQ
05/01	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	AQ
22/12	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial	AQ
19/12	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial	AQ
01/12	Altimmune Announces CEO Transition and Succession Plan	AQ
26/11	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference	AQ
12/11	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025	AQ
11/11	Presentation: A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	PU
11/11	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025	AQ